On-treatment tumor biopsies typically contained polyclonal TCR clonotypes specific to up to six autogene cevumeran-induced neoantigens, reaching frequencies of up to 7.2% (median, 1%; range, 0.04–7.2%) of infiltrating CD8+ TCR clonotypes (Fig. 3i, patient 90). Here, CD8A is linked to neoplasm.